124 related articles for article (PubMed ID: 22484323)
1. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation.
Skeens M; Pai V; Garee A; Termuhlen AM; Bajwa RP; Gross TG; Soni S
Bone Marrow Transplant; 2012 Nov; 47(11):1415-8. PubMed ID: 22484323
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
[TBL] [Abstract][Full Text] [Related]
3. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation.
Offer K; Kolb M; Jin Z; Bhatia M; Kung AL; George D; Garvin JH; Robinson C; Sosna J; Karamehmet E; Satwani P
Biol Blood Marrow Transplant; 2015 Mar; 21(3):496-502. PubMed ID: 25536217
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
8. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
Zohren F; Schroeder T; Czibere A; Fenk R; Bruns I; Kondakci M; Saure C; Haas R; Kobbe G
Bone Marrow Transplant; 2011 May; 46(5):747-55. PubMed ID: 20661230
[TBL] [Abstract][Full Text] [Related]
10. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Choi SW; Braun T; Chang L; Ferrara JL; Pawarode A; Magenau JM; Hou G; Beumer JH; Levine JE; Goldstein S; Couriel DR; Stockerl-Goldstein K; Krijanovski OI; Kitko C; Yanik GA; Lehmann MH; Tawara I; Sun Y; Paczesny S; Mapara MY; Dinarello CA; DiPersio JF; Reddy P
Lancet Oncol; 2014 Jan; 15(1):87-95. PubMed ID: 24295572
[TBL] [Abstract][Full Text] [Related]
12. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
[TBL] [Abstract][Full Text] [Related]
13. Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil.
Ram R; Herscovici C; Dahan D; Israeli M; Dreyer J; Peck A; Shpilberg O; Yeshurun M
Leuk Res; 2014 Aug; 38(8):913-7. PubMed ID: 24939215
[TBL] [Abstract][Full Text] [Related]
14. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
15. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
[TBL] [Abstract][Full Text] [Related]
17. Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis.
Hashmi H; Bhandari S; Kumar R; Tripathi P; Rhodes JB; Figg L; Baize T; Krem MM; Hegazi M; Emmons R
Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):232-237. PubMed ID: 32413417
[TBL] [Abstract][Full Text] [Related]
18. Minimum-Dose, Short-Term Methotrexate With Tacrolimus for Graft-vs-Host Disease Prophylaxis Following Unrelated Cord Blood Transplantation in Adults: A Retrospective Analysis at a Single Institution.
Iino M; Sato T; Sakamoto Y
Transplant Proc; 2021; 53(1):396-404. PubMed ID: 33308840
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
